Herpes zoster ophthalmicus in two women after Pfizer-BioNTech (BNT162b2) vaccine
J Med Virol
.
2022 Mar;94(3):817-818.
doi: 10.1002/jmv.27366.
Epub 2021 Oct 7.
Authors
Nicoletta Bernardini
1
,
Nevena Skroza
1
,
Alessandra Mambrin
1
,
Ilaria Proietti
1
,
Anna Marchesiello
1
,
Federica Marraffa
1
,
Giovanni Rossi
1
,
Salvatore Volpe
1
,
Ersilia Tolino
1
,
Concetta Potenza
1
Affiliation
1
Dermatology Unit "D. Innocenzi", Sapienza University of Rome, Polo Pontino, Italy.
PMID:
34585774
PMCID:
PMC8661555
DOI:
10.1002/jmv.27366
No abstract available
Publication types
Letter
MeSH terms
BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
Female
Herpes Zoster Ophthalmicus* / drug therapy
Humans
Vaccines*
Substances
COVID-19 Vaccines
Vaccines
BNT162 Vaccine